Kraft Heinz has lagged in the past year. RBC thinks that's about to change

RBC Capital Markets initiated Kraft Heinz with an outperform rating and a $32 price target, implying 29% upside from Wednesday's close. The firm expects 0.9% organic growth in 2027 versus 0.4% Street consensus, arguing that $700M of reinvestment in pricing, innovation and marketing should support a more material turnaround by 2027. The bullish call contrasts with cautious broader sentiment: 15 of 20 covering analysts rate the shares hold, while KHC has declined nearly 4% over the past year versus a 14% gain for the S&P 500.

Analysis

The investable issue is not whether KHC can create modest top-line growth, but whether incremental spending produces enough volume/mix to offset the margin drag before investors lose patience. At a mature staples multiple, even a 50bp-100bp organic-sales-growth beat can drive disproportionate rerating if it demonstrates that brand investment is generating repeat purchases rather than promotional pull-forward. The key read-throughs are scanner-data velocity, household penetration and price/mix: positive unit trends without an outsized increase in trade spend would validate operating leverage into 2027.

KHC's potential win comes partly at the expense of category peers with less room to fund innovation, notably CPB, CAG and SJM, while retailer private-label programs become the critical competitive constraint. If KHC uses its scale to defend shelf space through higher promotional allowances, the near-term beneficiary could be retailers rather than KHC shareholders; gross-margin recovery would then lag sales improvement. Conversely, products that expand usage occasions rather than cannibalize legacy SKUs can improve mix and reduce the risk that growth merely masks continued erosion in core brands.

Consensus skepticism creates an asymmetric setup, but the catalyst path is gradual: the next two quarterly results need to show improving volumes and no material guidance reset, while a more durable valuation change likely requires 2027 planning visibility over the next 6-12 months. The contrarian risk is that the reinvestment cycle becomes structurally permanent, leaving EBIT margins lower despite slightly better sales. Thesis failure would be two consecutive quarters of negative unit volume, promotional intensity rising faster than sales, or management signaling that margin restoration is deferred beyond 2027.

Key Decisions for Investors

• Initiate a 6-12 month long KHC position only on confirmation of a positive volume/market-share inflection in the next earnings release; target a rerating toward the analyst-implied upside, with a stop/review if organic sales miss consensus by more than 100bp or gross margin contracts year over year.
• Express the relative thesis as long KHC / short CPB or CAG over 6-9 months, sized beta-neutral. The spread should benefit if KHC's innovation converts into category share while competitors face the same retailer and private-label pressure without equivalent scale; close if KHC volume fails to outperform the selected peer for two reported quarters.
• For defined risk ahead of earnings, consider KHC 9-12 month call spreads rather than outright short-dated calls; the expected catalyst is multi-quarter evidence, making near-dated premium vulnerable to a muted initial reaction.
• Set an alert for Nielsen/IRI-style evidence of unit velocity, distribution gains and promotional depth. Do not add materially on management commentary alone: the missing proof is whether new-product sales are incremental and whether trade-spend growth remains below incremental gross profit.